| abstract |
The present invention relates to a pharmaceutical composition comprising a compound of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof; to the compound of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof for use as a medicament, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization, and to certain novel compounds of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof. Formula (I) wherein X 1 is CR 1 or N; X 2 is CR 2 or N; X 3 is CR 3 or N; X 4 is CR 4 or N; with the proviso that at most two of X 1 , X 2 , X 3 and X 4 are N; L 1 , L 2 are a bond or a bivalent radical such as C 1 -C 6 -alkylene or C 3 -C 8 -cycloalkylene; A is 3-, 4-, 5-, 6-, 7- or 8-membered saturated, partially unsaturated or maximally unsaturated carbocyclic ring which may carry one or more substituents R 9 ; or L 2 -A forms a group C 1 -C 6 -alkylene-OR 13 , C 1 -C 6 -alkylene-SR 14 or C 1 -C 6 -alkylene-NR 15 R 16 ; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 13 , R 14 , R 15 and R 16 are as defined in the claims and the description. |